Expression and prognostic signi cance of programmed death- ligand 1 (PD-L1) in Merkel cell carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27283933%3A_____%2F19%3A00006902" target="_blank" >RIV/27283933:_____/19:00006902 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Expression and prognostic signi cance of programmed death- ligand 1 (PD-L1) in Merkel cell carcinoma

Popis výsledku v původním jazyce

Purpose: To detect the expression of programmed death- ligand 1 (PD-L1) in Merkel cell carcinoma (MCC) and to determine the prognostic in uence of the PD-L1 expression. Methods: A total of 13 patients with MCC were retrospec- tively evaluated (12 patients with primary skin lesion, one patient was diagnosed as unknown primary MCC). All pa- tients underwent surgical resection. PD-L1 was determinat- ed by imunohistochemistry. Immunostaining results were evaluated semiquantitatively. The prognostic in uence of the expression of PD-L1 on overall survival (OS) was calculated with the Kaplan-Meier method and log-rank test. Results: PD-L1 positivity was detected in 8 patients (61.5%), in all cases the result was 1 . PD-L1 negativity was shown in the remaining 5 patients. In patients with PD-L1 positivity median OS was 42.1 months (95% CI 9.3-42.1) compared with median OS of 9.4 months (95% CI 2.1-80.9) in the group of patients without PD-L1 positivity (p=0.417). Conclusions: PD-L1 positivity was found in 61.5% of pa- tients with MCC. No prognostic signi cance of PD-L1 ex- pression for OS was demonstrated.

Název v anglickém jazyce

Expression and prognostic signi cance of programmed death- ligand 1 (PD-L1) in Merkel cell carcinoma

Popis výsledku anglicky

Purpose: To detect the expression of programmed death- ligand 1 (PD-L1) in Merkel cell carcinoma (MCC) and to determine the prognostic in uence of the PD-L1 expression. Methods: A total of 13 patients with MCC were retrospec- tively evaluated (12 patients with primary skin lesion, one patient was diagnosed as unknown primary MCC). All pa- tients underwent surgical resection. PD-L1 was determinat- ed by imunohistochemistry. Immunostaining results were evaluated semiquantitatively. The prognostic in uence of the expression of PD-L1 on overall survival (OS) was calculated with the Kaplan-Meier method and log-rank test. Results: PD-L1 positivity was detected in 8 patients (61.5%), in all cases the result was 1 . PD-L1 negativity was shown in the remaining 5 patients. In patients with PD-L1 positivity median OS was 42.1 months (95% CI 9.3-42.1) compared with median OS of 9.4 months (95% CI 2.1-80.9) in the group of patients without PD-L1 positivity (p=0.417). Conclusions: PD-L1 positivity was found in 61.5% of pa- tients with MCC. No prognostic signi cance of PD-L1 ex- pression for OS was demonstrated.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů